Evidence map›Paper›PMID 36173644›Full record

ReviewAging2022

A comprehensive review of pancreatic cancer and its therapeutic challenges.

Shan Jiang, Johan Bourghardt Fagman, Yunyun Ma, Jian Liu, Caroline Vihav, Cecilia Engstrom, Beidong Liu, Changyan Chen

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Metal-related cell death and its application in pancreatic cancer.Expert reviews in molecular medicine · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. RSC advances · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Shan JiangInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Johan Bourghardt FagmanInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Yunyun MaInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Jian LiuInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Caroline VihavInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Cecilia EngstromInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
Beidong LiuDepartment of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden.
Changyan ChenInstitute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.
University of Gothenburg · SESahlgrenska University Hospital · SENanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a devastating and lethal human malignancy with no curable chemo-treatments available thus far. More than 90% of pancreatic tumors are formed from ductal epithelium as pancreatic ductal adenocarcinoma (PDAC), which often accompany with the expression of mutant

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansPrognosisAntineoplastic Agentsetiologygenetic mutationspancreatic cancerprogressiontherapeutics

Identifiers

PMID36173644
PMCPMC9550249
OpenAlexW4297476727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.